News | November 01, 2023
Pfizer posts Q3 loss as Covid-19 revenues shrink
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
The company expects that this development could improve the strength of its application to the FDA for new drug approval
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Investment is additive to KKR’s existing health care growth strategy
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Subscribe To Our Newsletter & Stay Updated
